Warrington-based Windtree Therapeutics is currently exploring strategic alternatives to enhance shareholder value, including the possibility of acquisitions or being acquired, writes John George for the Philadelphia Business Journal.  

The company has enlisted the services of Ladenburg Thalmann & Co. Inc. to assess its options. 

Despite a challenging financial landscape, Windtree has taken significant steps to bolster its financial standing. These include a lucrative licensing agreement potentially worth over $138 million and the elimination of a $15 million contingent liability. 

Windtree, which shifted its focus to heart disease treatments following a 2018 merger with CVie Therapeutics Ltd., is advancing its cardiovascular portfolio, including its leading drug candidate istaroxime for cardiogenic shock and acute heart failure.  

Additionally, Windtree has recently entered into agreements to expand its developmental and commercial reach, particularly in Greater China, with Lee Pharmaceuticals.  

This includes upfront and milestone payments potentially totaling $138.35 million for istaroxime and other drug candidates.  

The company also resolved an agreement with Deerfield Management Co., exchanging rights for shares and cash payments. 

Read more about Windtree Therapeutics in the Philadelphia Business Journal.  

Windtree Therapeutics CEO Craig Fraser – Breaking Down Acute Heart Failure